SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...
A complement blood test measures how well complement proteins in your blood support immune defense. The complement system helps antibodies fight germs and clear foreign substances. Complement testing ...
The data will reveal optimization of the BiCE™ platform and show that Commit's second-generation BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies. With a ...
Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics Commit Biologics is pioneering a novel approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results